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With a newly World Health Organization (WHO)–prequalified typhoid conjugate vaccine (TCV), Gavi funding for eligible coun-
tries, and a WHO policy recommendation for TCV use, now is the time for countries to introduce TCVs as part of an integrated 
typhoid control program, particularly in light of the increasing burden of antimicrobial resistance. Continued vaccine development 
efforts will lead to secure supply of low-cost vaccines, and ongoing vaccine studies will provide critical vaccine performance data 
and inform optimal deployment strategies, in both routine use and in outbreak settings. TCV programs should include thoughtful 
communication planning and community engagement to counter vaccine hesitancy.
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This is a historic moment for typhoid control. Despite continuing 
gaps, we now have a more refined understanding of the burden 
of typhoid fever, as well as improved tools available to reduce the 
burden dramatically. Recent multicenter surveillance studies in 
Africa and Asia have also improved understanding of the age and 
geographic distribution of typhoid, demonstrating that it is an ill-
ness that affects young children as well as school age children living 
in both urban and rural settings [1–3]. These and other epidemio-
logical data informed the recommendations by the World Health 
Organization (WHO) Strategic Advisory Group of Experts on 
Immunization in October 2017 on the use of typhoid conjugate vac-
cine (TCV) for typhoid control [4]. Shortly after this recommenda-
tion was issued, Bharat Biotech’s (Hyderabad, India) Typbar-TCV 
(composed of Vi polysaccharide conjugated to tetanus toxoid) 
became the first TCV to obtain WHO prequalification [5]. Gavi, 
the Vaccine Alliance, a public-private partnership that channels fi-
nancing and works with other alliance partners to support lower-
income countries for equitable use of vaccines, approved funding 
support for TCV use in Gavi-eligible countries in November 2017 
[6]. The Typhoid Vaccine Acceleration Consortium (TyVAC), 
a partnership between the University of Maryland, Oxford 
University, and PATH, is assessing the efficacy of this vaccine at 
field sites in Bangladesh, Nepal, and Malawi [7].
Since the first WHO recommendation in 2000 for the 
unconjugated Vi polysaccharide (Vi-PS) and live-attenuated 
Ty21a vaccines, considerable progress in vaccination as a ty-
phoid control strategy has been realized. The updated 2018 
WHO policy on typhoid vaccination includes a first-time rec-
ommendation for the routine use of TCVs, including in chil-
dren <2 years of age in countries with a high burden of disease 
and/or high rate of antimicrobial-resistant Salmonella Typhi; 
these children would not have been protected by either the 
Vi-PS or Ty21a vaccine. A single intramuscular dose of TCV is 
recommended for primary vaccination of infants and children 
from 6 months of age and adults up to 45 years of age, with an 
option for catch-up campaigns in children up to 15 years of age 
[8]. Furthermore, the use of TCV is recommended in preference 
to the Vi polysaccharide and Ty21a vaccines in both routine im-
munization programs and in response to confirmed outbreaks.
Historical precedents in many industrialized countries teach 
us that typhoid control is feasible through establishment and con-
tinued maintenance of water and sewage systems that ensure that 
food and drinking water are separated from human fecal con-
tamination [9, 10]. However, the challenge of making sustainable 
improvements to water and hygiene infrastructure is yet to be over-
come in many endemic countries and requires significant time and 
investment, particularly given additional demands on the existing 
water supply caused by rapid urbanization and climate change 
[10]. Yet another challenge, and one that makes a strong case for 
prioritizing parallel short-term control measures, is the increasing 
prevalence of antimicrobial-resistant strains of S. Typhi [11–13].
FUTURE AREAS OF FOCUS: NEW VACCINES AND 
SURVEILLANCE
Reducing the global burden of typhoid is a focus of both inter-
national health organizations and major global health funders. 
A central tenet of this focus is optimal deployment of vaccines in 
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endemic regions, and critical to its success is sustainable, secure 
vaccine supply [6, 8, 14, 15]. There is a robust pipeline of ty-
phoid conjugate vaccine candidates in clinical development [16]. 
Among the more advanced candidates, is a TCV composed of 
Vi polysaccharide conjugated to diphtheria toxoid, developed by 
the International Vaccine Institute, which is undergoing clinical 
development through a technology transfers to SK Bioscience 
in Korea, PT BioFarma in Indonesia, and Incepta Vaccine Ltd. 
in Bangladesh [16]. Another candidate, TCV with a non-toxic 
mutant of diptheria as carrier protein (Vi-CRM197) is being 
developed by Biological E Ltd. in India through a technology 
transfer from the Novartis Vaccines Institute for Global Health 
(now GSK Vaccines Institute for Global Health) [16]. The TCV 
candidates from SK Bioscience, PT BioFarma and Biological 
E Ltd. are currently being evaluated in clinical studies in the 
Phillipines, Indonesia, and India respectively [16].
While the recent prequalification of the Bharat Biotech TCV 
and the pipeline of TCV candidates augur well for a healthy vac-
cine market, there continues to be a need to understand the im-
pact and operational feasibility of large-scale TCV deployment 
strategies. The TCV studies being conducted under the leader-
ship of TyVAC will provide field efficacy data, outcomes that are 
made more critical by the fact that national licensure of the vac-
cine was based on immunogenicity data [7]. As with all new vac-
cine introductions, as countries begin to introduce TCVs into 
routine use, it will be important to assess their impact on disease 
and to track coverage and sustainability of routine TCV use over 
time. There are also important operational research questions 
that need to be addressed about how best to target TCV catch-up 
campaigns to maximize health impact. Additionally, as typhoid 
is a disease with outbreak potential, understanding how, when, 
and where to deploy TCVs to prevent and/or halt the spread of 
an outbreak continues to be an important issue.
To improve monitoring of the disease burden, the WHO re-
cently released surveillance standards for S. Typhi and other in-
vasive salmonelloses [17] and recommended laboratory-based 
surveillance as a minimum standard. Because blood-culture–
based surveillance is time and resource intensive and has low 
sensitivity [18], there is a need to understand the role of addi-
tional methods to assess enteric fever burden in resource-limited 
settings. Initially, new methods should be tested and validated 
at sites where blood culture surveillance has already been estab-
lished. New methods could include environmental surveillance 
data, gene expression signatures [19], and serological markers 
of current or past infection [20]. Once validated, the outputs of 
such assessments could support country decision making on 
TCV introduction, as well as determine optimal vaccination 
strategies. Ideally, these efforts would be incorporated into inte-
grated surveillance systems encompassing additional pathogens.
The ongoing rise of antimicrobial resistance (AMR) in S. Typhi 
is a major factor contributing to the need for vaccine introduc-
tion and increased surveillance [21]. The US Centers for Disease 
Control and Prevention lists S.Typhi, with ongoing emergence of 
multi-drug resistant strains as a ‘serious threat’ [22]. In 2017, the 
WHO included Salmonella species in its list of antibiotic-resistant 
“priority pathogens” to guide and promote research and develop-
ment of new antibiotics to address the global growth of AMR [23]. 
The emergence of extensively drug-resistant S. Typhi isolates with 
resistance against chloramphenicol, ampicillin, trimethoprim-
sulfamethoxazole, fluoroquinolones, and third-generation 
cephalosporins enhances the threat of infections with limited 
treatment options [24]. The widespread uptake of TCVs, with 
their improved immunogenicity in children and longer duration 
of protection, has potential to combat AMR in typhoid endemic 
areas, provided sufficient vaccine coverage levels are achieved, 
particularly in groups at greatest risk of disease. As such, TCVs 
could both reduce the number of circulating drug-resistant strains 
of S. Typhi and reduce the overall incidence of febrile illnesses, 
thereby reducing the need for and exposure to antibiotics.
DEPLOYING NEW VACCINES: PUBLIC ACCEPTANCE 
AND IMPACT ON GLOBAL SECURITY
Increasing global interconnectedness and the resultant growing 
risk of infectious disease spread across wide geographies make 
it imperative that new vaccines and improved surveillance are 
accompanied by a better understanding of local perceptions 
about specific vaccines and the diseases that they aim to prevent.
In 2019, the WHO named “vaccine hesitancy,” as one of 10 
global health threats, alongside Ebola, AMR, and climate change 
[25]. Global surveys show that, on average, populations’ belief in 
the importance of vaccines and acceptance of routine vaccina-
tion is relatively high, although highly uneven across different 
settings [26, 27]. There is concern that people’s confidence in 
vaccines is eroding and can result in falling vaccination rates. 
The large number of measles outbreaks in recent years illustrates 
this in part (access to vaccines being another important cause in 
many regions), with Europe alone having nearly 85 000 cases of 
measles in 2018 [28]. The introduction of new vaccines impact 
vaccine coverage in different ways; in some cases improving cov-
erage, and in others disrupting immunization services. For ex-
ample, in the Philippines, it has been demonstrated that reduced 
public confidence due to safety scares around one new vaccine 
can spill over to create reluctance around and refusal of other 
vaccines. This was particularly evident by the increase in mea-
sles vaccination refusals, which resulted in large-scale measles 
outbreaks [29]. These are important lessons to bear in mind 
ahead of the introduction of the newly available TCV. The im-
portance of community engagement, from the early stages of 
considering the introduction of a new vaccine or new immu-
nization initiative, is well established, as are the consequences 
of not adequately engaging stakeholders. Vaccine program 
challenges in the context of conflict and insecurity, which the 
global polio eradication initiative has faced in the last mile of a 
multidecade effort, is another area ripe with lessons learned [30].
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Similar to many vaccine-preventable diseases, typhoid thrives 
in conditions of sociopolitical breakdown. Past conflicts have 
exposed refugees in multiple locations to the catastrophic im-
pact of infected food and water sources. For example, crowding 
and degraded living conditions, including poor sanitation and 
hygiene, have contributed to typhoid outbreaks in Bosnia-
Herzegovina Ivory Coast, Rwanda, Tanzania, South Sudan, 
North Darfur, and Syria [31–34]. In most instances, these 
outbreaks occurred in refugee camps characterized by dense 
population, vulnerable infrastructures, and strained resources. 
In addition to detection and treatment programs, vaccination 
has the potential to contribute significantly to successful di-
sease control in such circumstances [35]. More difficult to ad-
dress can be social problems caused or aggravated by outbreaks. 
In conflict areas, these can include rumors, stigmatization, 
and conflicts within and between vulnerable populations. In 
situations like these, successful disease control requires an effec-
tive and rapid interplay between disease surveillance, medical 
intervention, and culturally appropriate information policies.
CONCLUSIONS
With the availability of improved typhoid disease burden data 
and low-cost TCVs, countries have a unique opportunity to im-
plement TCVs as part of an integrated typhoid control program. 
Given the increasing threat of AMR, and the longer time horizon 
of improving water and sanitation infrastructure, TCVs are a 
critical tool in both immediate and long-term typhoid control 
efforts. Routine use of TCVs in endemic countries has consider-
able potential to reduce the burden of disease, and TCVs have a 
vital role to play in outbreak control, particularly in vulnerable 
populations. It is important to implement lessons learned from 
other vaccine introductions and to represent the full societal 
value of TCV programs through thoughtful advocacy and com-
munications planning to counter vaccine hesitancy.
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